November 3, 2010
This one-day symposium focused on European biotechnology companies conducting early-stage high risk research for Alzheimer’s disease that complement approaches in advanced clinical trials. This satellite meeting was held in conjunction with the 3rd Clinical Trials for Alzheimer’s Disease (CTAD) conference. The symposium attracted approximately 250 attendees from all over the world and all levels of academia, government, and industry.
For more information, please visit our Conference Website